Werewolf Therapeutics to Showcase Posters at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Oct 03 2025

0mins

Source: Globenewswire

Company Announcement: Werewolf Therapeutics, Inc. will present three posters at the Society for Immunotherapy of Cancer’s 40th Annual Meeting from November 5-9, 2025, focusing on their innovative cancer treatments.
Research Highlights: The posters will cover topics such as enhanced antitumor activity in mice, the development of conditional T cell engagers to reduce toxicity, and pharmacokinetic insights into their IL-2 INDUKINE prodrug WTX-124.
Company Overview: Werewolf Therapeutics specializes in conditionally activated therapeutics designed to stimulate the immune system for cancer treatment, utilizing their proprietary PREDATOR platform.
Product Development: The company is advancing its clinical candidates, WTX-124 and WTX-330, for solid tumors and is also developing INDUCER molecules, with the first candidate targeting STEAP1 for prostate cancer.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for NVDA?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy NVDA?

Get Started Free